MEDADVISOR LIMITED (MDR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MDR - MEDADVISOR LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.83
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.29

22 Nov
2024

-0.010

OPEN

$0.30

-3.33%

HIGH

$0.31

748,484

LOW

$0.29

TARGET
$0.62 113.8% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
MDR: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.1 0.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A - 28.6% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 290.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx122.1 M
Book Value Per Share xxxxxxxxxxxxxxx9.4
Net Operating Cash Flow xxxxxxxxxxxxxxx5.2 M
Net Profit Margin xxxxxxxxxxxxxxx0.65 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx1.58 %
Return on Invested Capital xxxxxxxxxxxxxxx1.41 %
Return on Assets xxxxxxxxxxxxxxx0.81 %
Return on Equity xxxxxxxxxxxxxxx1.58 %
Return on Total Capital xxxxxxxxxxxxxxx4.29 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx5.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx13 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx13 M
Goodwill - Gross xxxxxxxxxxxxxxx46 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx16 M
Price To Book Value xxxxxxxxxxxxxxx5.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx1.8 M
Capex % of Sales xxxxxxxxxxxxxxx1.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx98 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx21 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

08/08/2024

-1

No Rating

-

MedAdvisor recorded June quarter operating revenue up 32% and FY24 revenue up 24.6%, in line with guidance. A full result release is due later in the month.

Management is happy with the strong momentum throughout FY24 to date which has continued into 1Q25. The strong performance over the year highlights the critical role of its innovative solutions for clients in the US and A&NZ, Morgans suggests.

The broker does not provide a rating or target, rather is monitoring the stock.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

06/11/2024

1

Buy

$0.57

96.55%

Canaccord Genuity reports a weaker-than-expected first quarter for MedAdvisor in FY25, with revenue up 3.5% year-on-year to $26.3m, driven by 4.1% growth in the US segment.

The analysts expect a stronger 2Q performance. Should this outcome not eventuate, the broker would lose some faith as costs will increase in the near-term due to the Transformation 360 Program.

While the company's long-term potential remains intact, the broker also suggests near-term growth may be constrained by broader industry cost pressures.

Canaccord retains a Buy rating and a target price of 57c.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.00 cents.
Access Extra Coverage Research History >

MDR STOCK CHART

FNArena News on MDR

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
3
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View
4
Australian Broker Call *Extra* Edition – Nov 06, 2024

Nov 06 2024 - Daily Market Reports
5
Rudi’s View: US Earnings & The Election

Oct 31 2024 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia